1. Home
  2. BEEP vs CRDL Comparison

BEEP vs CRDL Comparison

Compare BEEP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobile Infrastructure Corporation

BEEP

Mobile Infrastructure Corporation

N/A

Current Price

$2.91

Market Cap

113.7M

Sector

Finance

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$2.00

Market Cap

132.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BEEP
CRDL
Founded
2015
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.7M
132.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
BEEP
CRDL
Price
$2.91
$2.00
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.50
$8.50
AVG Volume (30 Days)
49.1K
1.2M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,075,000.00
N/A
Revenue This Year
$5.77
N/A
Revenue Next Year
$22.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$0.88
52 Week High
$4.07
$2.00

Technical Indicators

Market Signals
Indicator
BEEP
CRDL
Relative Strength Index (RSI) 69.99 76.75
Support Level $2.61 $0.95
Resistance Level $3.12 N/A
Average True Range (ATR) 0.32 0.13
MACD 0.03 0.03
Stochastic Oscillator 87.29 90.44

Price Performance

Historical Comparison
BEEP
CRDL

About BEEP Mobile Infrastructure Corporation

Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: